Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: AMPE: Ampio has […]
Catalyst Watch – Vol. 3, Edition 2 (1/27/15)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: *** Check out […]
Catalyst Watch – Vol. 3, Edition 1 (1/15/15)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: RMTI: I sold […]
Catalyst Watch – Vol. 2, Edition 36 (12/30/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: RMTI: I remain […]
Catalyst Watch – Vol. 2, Edition 35 (12/11/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: RMTI: Last week […]
Catalyst Watch – Vol. 2, Edition 34 (12/5/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: RMTI: The company […]
Catalyst Watch – Vol. 2, Edition 33 (11/20/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: RMTI: The company […]
Catalyst Watch – Vol. 2, Edition 32 (11/5/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Strategy Updates RMTI: […]
Catalyst Watch – Vol. 2, Edition 31 (10/23/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Strategy Updates/Comments CEMP:Top […]
MRK – A Falling Knife Or a Golden Opportunity
Merck & Co. Inc. (MRK) -NYSE Many speculation going around the huge drop in MRK’s share price in just one week, dropping from the $60.18 (closing on 10/08) to reach the low of $52.49 today, but bouncing back sharply to trade around the support line $53.44. Some speculation of De-risking as we get closer to […]
Catalyst Watch – Vol. 2, Edition 30 (10/14/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: CEMP:Top line (efficacy/safety) […]
CNAT – A Quick Chart Update
Conatus Pharmaceuticals Inc. (CNAT) –Nasdaq CNAT was trading within a downtrend channel since June 16th after reaching the high of $9.90, finding a base around the $6.00 weekly support line as mentioned several time at Chimera’s twitter private feed and was moving side way in a consolidation mode for two weeks. J: $CNAT bouncing 8.5% […]
Catalyst Watch – Vol. 2, Edition 29 (10/2/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: CEMP:Top line (efficacy/safety) […]
Catalyst Watch – Vol. 2, Edition 28 (9/26/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: CNAT: I continue […]
Catalyst Watch – Vol. 2, Edition 27 (9/19/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: CNAT: Holding shares […]
Recent Option Activity (9/10 ~ 9/11)
The following stocks had recent and notable activity in their options: $MRK (9/10): 12,800 JAN15 50.0 strike Calls were sold (stock at $60.56) for 10.70 or total proceeds of $13.7 million. This trade is likely part of a larger “dividend capture” strategy (see: http://www.businessinsider.com/options-dividend-trade-strategy-2012-9) and should be viewed as neutral (not bearish or bullish). $SNSS […]
Catalyst Watch – Vol. 2, Edition 26 (9/9/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: AEZS: PDUFA is […]
Catalyst Watch – Vol. 2, Edition 25 (8/26/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: AEZS: PDUFA is […]
Recent Option Activity (8/6 ~ 8/12)
The following stocks had recent and notable activity in their options: $INFI (8/6): 3,822 SEP 10.0 strike Puts were sold (stock at $9.98) for 0.45 or total proceeds of $171,990. This is a bullish/neutral strategy where the seller makes money as long as the stock settles above $9.55 by September expiration. $FOLD (8/12): 1,100 SEP […]
Catalyst Watch – Vol. 2, Edition 24 (8/11/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: AEZS: PDUFA is […]
